These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study. Terao T; Oga T; Nozaki S; Ohta A; Ohtsubo Y; Yamamoto S; Zamami M; Okada M Acta Psychiatr Scand; 1995 Sep; 92(3):220-4. PubMed ID: 7484202 [TBL] [Abstract][Full Text] [Related]
6. Antipsychotic effects of lithium in schizophrenia. Alexander PE; van Kammen DP; Bunney WE Am J Psychiatry; 1979 Mar; 136(3):283-7. PubMed ID: 369396 [TBL] [Abstract][Full Text] [Related]
7. [Schizophrenia and treatment with lithium salts. Current data from the literature]. Matot JP; Olié JP; Lôo H Encephale; 1983; 9(1):49-57. PubMed ID: 6872934 [TBL] [Abstract][Full Text] [Related]
8. Methylphenidate challenge as a predictor of relapse in schizophrenia. Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506 [TBL] [Abstract][Full Text] [Related]
9. Lithium response in good prognosis schizophrenia. Hirschowitz J; Casper R; Garver DL; Chang S Am J Psychiatry; 1980 Aug; 137(8):916-20. PubMed ID: 7416291 [TBL] [Abstract][Full Text] [Related]
10. Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients. van Kammen DP; Docherty JP; Marder SR; Bunney WE Psychiatry Res; 1981 Jun; 4(3):313-25. PubMed ID: 6115437 [TBL] [Abstract][Full Text] [Related]
12. Relapse in patients with shifting RDC diagnoses treated with lithium alone. Glazer WM; Sheard MH J Clin Psychiatry; 1982 Apr; 43(4):134-6. PubMed ID: 7068543 [TBL] [Abstract][Full Text] [Related]
13. Lithium and chlorpromazine in psychotic inpatients. Braden W; Fink EB; Qualls CB; Ho CK; Samuels WO Psychiatry Res; 1982 Aug; 7(1):69-81. PubMed ID: 6813888 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Davis KL; Berger PA Biol Psychiatry; 1978 Feb; 13(1):23-49. PubMed ID: 146524 [TBL] [Abstract][Full Text] [Related]
15. [Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)]. Modestin J; Schwartz RB; Hunger J Pharmakopsychiatr Neuropsychopharmakol; 1973 Nov; 6(6):300-4. PubMed ID: 4603643 [No Abstract] [Full Text] [Related]
16. Equipercentile linking of the BPRS and the PANSS. Leucht S; Rothe P; Davis JM; Engel RR Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639 [TBL] [Abstract][Full Text] [Related]
17. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091 [TBL] [Abstract][Full Text] [Related]
18. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Garver DL; Bissette G; Yao JK; Nemeroff CB Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695 [TBL] [Abstract][Full Text] [Related]